Synthesis and comparison of the meta-analyses evaluating the efficacy of memantine in moderate to severe stages of alzheimer's disease

CNS Drugs

Volumn 27, Issue 7, 2013, Pages 573-582

  Rive, Benoît ^a   Gauthier, Serge ^b   Costello, Sophie ^c   Marre, Caroline ^a   François, Clément ^a  

^a Lundbeck   (France)

^b MCGILL UNIVERSITY   (Canada)

^c Department of Health Economics and Statistics   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

MEMANTINE; PLACEBO;

ADD ON THERAPY; ALZHEIMER DISEASE; ARTICLE; BEHAVIOR; BEHAVIOR DISORDER; CLINICAL TRIAL (TOPIC); COGNITION; DAILY LIFE ACTIVITY; DISEASE COURSE; DISEASE SEVERITY; DRUG EFFICACY; DRUG WITHDRAWAL; EFFECT SIZE; HUMAN; INTENTION TO TREAT ANALYSIS; META ANALYSIS (TOPIC); MINI MENTAL STATE EXAMINATION; MONOTHERAPY; OFF LABEL DRUG USE; PRIORITY JOURNAL; PSYCHOSIS; RANDOMIZATION; SYSTEMATIC REVIEW (TOPIC);

ALZHEIMER DISEASE; CLINICAL TRIALS AS TOPIC; EXCITATORY AMINO ACID ANTAGONISTS; HUMANS; MEMANTINE; META-ANALYSIS AS TOPIC; RECEPTORS, N-METHYL-D-ASPARTATE; SEVERITY OF ILLNESS INDEX;

EID: 84880554648     PISSN: 11727047     EISSN: 11791934     Source Type: Journal    
DOI: 10.1007/s40263-013-0074-x     Document Type: Article

References (39)

1. McShane R, Areosa Sastre A, Minakaran N. Memantine for dementia. Cochrane Database Syst Rev. 2006;(2):CD003154.
2. Winblad B, Jones RW, Wirth Y, Stoffler A, Mobius HJ. Memantine in moderate to severe Alzheimer's disease: a meta-analysis of randomised clinical trials. Dement Geriatr Cogn Disord. 2007;24(1):20-7.
3. Eastwood R, Reisberg B. Mood and behaviour. In: Gauthier S, editor. Clinical diagnosis and management of Alzheimer's disease. Boston: Butterworth-Heinemann; 1996. p. 175-189.
4. European Medicines Agency Committee for Medicinal Products for Human Use (CHMP). Guideline on medicinal products for the treatment of Alzheimer's disease and other dementias. 2008.
5. Alzheimer's Disease International. Statistics. 2011.
6. Olesen J, Gustavsson A, Svensson M, Wittchen HU, Jonsson B. The economic cost of brain disorders in Europe. Eur J Neurol 2012;19:155-162.
7. Winblad B, Brodaty H, Gauthier S, Morris JC, Orgogozo JM, Rockwood K, Schneider L, Takeda M, Tariot P, Wilkinson D. Pharmacotherapy of Alzheimer's disease: is there a need to redefine treatment success? Int J Geriatr Psychiatry. 2001;16:653-66.
8. Geldmacher DS, Frolich L, Doody RS, Erkinjuntti T, Vellas B, Jones RW, Banerjee S, Lin P, Sano M. Realistic expectations for treatment success in Alzheimer's disease. J Nutr Health Aging. 2006;10:417-29.
9. Danysz W, Parsons CG, Mobius HJ, Stoffler A, Quack G. Neuroprotective and symptomatological action of memantine relevant for Alzheimer's disease - a unified glutamatergic hypothesis on the mechanism of action. Neurotox Res. 2000;2(2-3):85-97.
10. European Medicines Agency. Annex I: summary of product characteristics (Ebixa). Last updated 2011.
11. Reisberg B, Doody R, Stoffler A, Schmitt F, Ferris S, Mobius HJ. Memantine in moderate-to-severe Alzheimer's disease. N Engl J Med. 2003;348(14):1333-41.
12. van Dyck C. A 24-week randomized, controlled trial of memantine in patients with moderate-to-severe Alzheimer disease. Alzheimer Dis Assoc Disord. 2007;21(2):136-43.
13. Bakchine S. Memantine treatment in patients with mild to moderate Alzheimer's disease: results of a randomised, double-blind, placebo-controlled 6-month study. J Alzheimers Dis. 2008;13(1):97-107.
14. Peskind ER, Potkin SG, Pomara N, Ott BR, Graham SM, Olin JT, et al. Memantine treatment in mild to moderate Alzheimer disease: a 24-week randomized, controlled trial. Am J Geriatr Psychiatry. 2006;14(8):704-15.
15. Tariot PN, Farlow MR, Grossberg GT, Graham SM, McDonald S, Gergel I. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. JAMA. 2004;291(3):317-24.
16. Porsteinsson AP, Grossberg GT, Mintzer J, Olin JT. Memantine treatment in patients with mild to moderate Alzheimer's disease already receiving a cholinesterase inhibitor: a randomized, double-blind, placebo-controlled trial. Curr Alzheimer Res. 2008;5(1):83-9.
17. Doody RS, Tariot PN, Pfeiffer E, Olin JT, Graham SM. Meta-analysis of six-month memantine trials in Alzheimer's disease. Alzheimers Dement. 2007;3(1):7-17.
18. IQWiG. Institut für Qualität und im Wirtschaftlichkeit Gesundheitswesen. Memantine Alzheimer bei Demenz. Abschlussbericht. IQWiG-Berichte-Jahr: 2009 No. 59. https://www.iqwig.de/download/A05-19C- Abschlussbericht-Memantin-bei-Alzheimer-Demenz.pdf. 2009. Accessed 10 Jan 2013.
19. PenTAG. Peninsula Technology Assessment Group (PenTAG), University of Exeter. The Effectiveness and cost-effectiveness of donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (review of TA111): a systematic review and Economic model. 2010. http://guidance.nice.org. uk/TA/WaveR111/1/AssessmentReport). Accessed 10 Jan 2013.
20. Lundbeck. A randomized, double-blind, placebo-controlled evaluation of the efficacy and safety of memantine in patients with dementia of the Alzheimer's type. http://wwwlundbecktrialscom/Data/PDFs/10116-Final-11Oct2006- CTRSpdf. 2006. Accessed 2 May 2013.
21. Lundbeck. Memantine for the Treatment of moderate to severe Alzheimer's disease. Lundbeck response to the technology assessment report. 4th Aug 2010.
22. PenTAG. AChEIs and memantine for Alzheimer's disease. PenTAG accessed responses to comments. 17th Aug 2010.
23. NICE. Alzheimer's disease - donepezil, galantamine, rivastigmine and memantine (review): appraisal consultation document. 2010. http://guidance.nice. org.uk/TA/WaveR111/1/Consultation/DraftGuidance. 2010. Accessed 10 Jan 2013.
24. The Cochrane Collabration. Module contents: Diversity and heterogeneity. http://www.cochrane-net.org/openlearning/html/mod13-5.htm. 2002.
25. Molnar FJ, Man-Son-Hing M, Hutton B, Fergusson DA. Have last-observation-carried-forward analyses caused us to favour more toxic dementia therapies over less toxic alternatives? A systematic review. Open Med. 2009;3:e31-50.
26. Vellas B, Andrieu S, Sampaio C, Coley N, Wilcock G. Endpoints for trials in Alzheimer's disease: a European task force consensus. Lancet Neurol. 2008;7:436-50.
27. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557-60.
28. Wilcock GK, Ballard CG, Cooper JA, Loft H. Memantine for agitation/aggression and psychosis in moderately severe to severe Alzheimer's disease: a pooled analysis of 3 studies. J Clin Psychiatry. 2008;69(3):341-8.
29. Lundbeck. Memantine for the treatment of Alzheimer's disease - NICE submission of evidence. 2010. http://guidance.nice.org.uk/TA/WaveR111/1/ Consultation/EvaluationReport/ManufacturerSubmissions/LundbeckUK/pdf/English. Accessed 02 May 2013.
30. Ryu SH, Katona C, Rive B, Livingston G. Persistence of and changes in neuropsychiatric symptoms in Alzheimer disease over 6 months: the LASER-AD study. Am J Geriatr Psychiatry. 2005;13(11):976-83.
31. Selbaek G, Kirkevold O, Engedal K. The course of psychiatric and behavioral symptoms and the use of psychotropic medication in patients with dementia in Norwegian nursing homes - a 12-month follow-up study. Am J Geriatr Psychiatry. 2008;16(7):528-36.
32. Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gornbein J. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology. 1994;44:2308-14.
33. Cummings JL. The Neuropsychiatric Inventory: assessing psychopathology in dementia patients. Neurology. 1997;48:S10-6.
34. Gauthier S, Loft H, Cummings J. Improvement in behavioural symptoms in patients with moderate to severe Alzheimer's disease by memantine: a pooled data analysis. Int J Geriatr Psychiatry. 2008;23(5):537-45.
35. Matsumoto N, Ikeda M, Fukuhara R, Shinagawa S, Ishikawa T, Mori T, Toyota Y, Matsumoto T, Adachi H, Hirono N, Tanabe H. Caregiver burden associated with behavioral and psychological symptoms of dementia in elderly people in the local community. Dement Geriatr Cogn Disord. 2007;23:219-24.
36. Homma A, Kitamura S, Yoshimura I. Asubio IE-2101: Efficacy of memantine in patients with moderately severe to severe Alzheimer's disease in Japan (dose-finding study). Presented at the 11th congress of the European Federation of Neurological Societies, Brussels, Belgium, Aug 2007.
37. Forest MEM-MD-22 http://www.forestclinicaltrials.com/CTR/CTRController/ CTRViewPdf?-file-id=scsr/SCSR-MEM-MD-22-final.pdf. Accessed 10 Jan 2013.
38. Wilkinson D, Fox NC, Barkhof F, Phul R, Lemming O, Scheltens P. Lundbeck 10112: memantine and brain atrophy in Alzheimer's disease: a 1-year randomized controlled trial. J Alzheimers Dis. 2012;29(2):459-69.
39. Gauthier S, Herrmann N. Lundbeck 10158: results of the Canadian study of memantine in moderately agitated patients. Presented at the Canadian conference on dementia, Montreal, Nov 2011.